The ability to degrade amyloid A fibrils was studied in the serum of 31 patients with amyloidosis associated with rheumatoid arthritis, 33 patients with rheumatoid arthritis without amyloidosis, and 47 healthy controls. Fibrillar amyloid A protein and the radial diffusion method were used.
Introduction
Amyloidosis is characterised by extracellular deposition ofprotein fibrils with anti-parallel 3-pleated sheet conformation.' In amyloidosis secondary to chronic inflammation, including rheumatic diseases,2 these deposits contain amyloid A protein,3 which structurally has been regarded as a degradation product of serum amyloid A protein.' Serum amyloid A is an acutephase protein, which occurs in high concentrations in amyloidosis and in rheumatic, inflammatory, and neoplastic diseases.6 7 We have examined the ability of serum to degrade amyloid A fibrils in patients with rheumatoid arthritis with or without amyloidosis and in healthy controls. We also measured serum amyloid A, C-reactive protein, and at,-antitrypsin concentrations.
Patients and methods
We studied two groups of patients with classic or definite rheumatoid arthritis (American Rheumatism Association criteria). One group comprised 13 men and 20 women (mean age 55-4 years), none of whom had signs of amyloidosis (confirmed by biopsy in a few cases); and the other comprised 12 men and 19 women (mean age 51-7 years), all of whom had biopsy-proved amyloidosis. Forty-seven healthy blood donors (31 men, 16 women; mean age 36-6 years) served as controls. Table I shows the duration of active rheumatoid arthritis, presence of rheumatoid factor in serum, serum creatinine concentrations, and degree of proteinuria in the two groups of patients.
The ability of serum to degrade fibrillar amyloid A protein was studied by radial diffusion in agarose gel containing amyloid A fibrils.' 9 Briefly, amyloid A fibrils were extracted with distilled water"°from an amyloid human kidney and suspended in 1% agarose in phosphate-buffered saline, pH 7-3, at a concentration of 0-5 g/l. Wells (4 mm diameter) were punched in the amyloid-agarose layer (1-5 mm thick) and filled with 10 1l serum samples. After overnight incubation at room temperature the diameters of the lysed areas around the wells were measured. A pooled sample of sera from 100 blood donors was used as standard and the splitting activity expressed as a percentage of the activity of the standard. The within-assay coefficient of variation of the method was 4-8% and the between-assay variation 13-6%. 9 The possible influence of renal insufficiency on the amyloid-splitting ability of serum was tested in 29 patients with impaired kidney function but with no signs of joint disease.
Serum amyloid A, C-reactive protein, and ocl-antitrypsin concentrations were determined by radial immunodiffusion. Purified amyloid A protein was used as standard for serum amyloid A.
Results
Amyloid-A-degrading activity was significantly reduced in both groups of patients compared with the controls (p < 0-001) (table II) and significantly lower in the patients with amyloidosis (mean 58% of standard) than in those with rheumatoid arthritis alone (mean 78% of standard) (p <0-001). In the separate group of 29 patients with impaired kidney function and no sign of joint disease renal insufficiency by itself did not affect the amyloid-splitting ability of serum. In that group mean values were: amyloid-A-degrading activity 101 ± 16% SD of standard, ot5-antitrypsin concentration 106 ±34% of standard, and serum creatinine concentration 571 ±306 emol/l (6-5± 3-5 mg/100 ml). The amount of urinary protein in five patients with glomerular disease and heavy proteinuria also did not influence the amyloid-A-degrading activity of serum.
Mean serum amyloid A and C-reactive protein concentrations were significantly higher in the two groups of patients with rheumatoid Mean al-antitrypsin concentrations were higher in patients with rheumatoid arthritis alone (p < 0 01) and complicated by amyloidosis (p < 0 001) than in the controls (table II) . The difference between the two groups of patients, however, was not significant.
The effect of the activity of rheumatoid arthritis on the ability of serum to degrade amyloid A was studied in a woman with relapsing disease not complicated by amyloidosis (fig 1) . During remission the raised serum concentrations of C-reactive protein, amyloid A, and otl-antitrypsin and decreased amyloid-A-degrading activity returned towards normal. A negative correlation was observed between the arthritis than in the controls ( degrading activity and ax-antitrypsin values (r = -0-68; p < 0-05).
Purified al-antitrypsin inhibited degrading activity. The degree of inhibition bore a linear relation to the amount of a1-antitrypsin added (fig 2) .
Discussion
We found that patients with rheumatoid arthritis complicated by amyloidosis had significantly lower amyloid-A-degrading activity in serum than healthy subjects or patients with rheumatoid arthritis but without signs of amyloidosis. This has important implications in the molecular pathogenesis of rheumatoid amyloidosis. Though in our study, as in some others,6 71 serum amyloid A concentrations were increased in rheumatoid arthritis, the difference between patients with amyloidosis and those with rheumatoid arthritis alone was not significant. Moreover, an increase in serum amyloid A seems to be a general response of the organism to various stimuli.6 Additional factors are therefore concerned in the molecular mechanisms that lead to amyloidosis. One of these is reduced amyloid-A-degrading ability in the serum of patients with concomitant amyloidosis.
Patients with familial Mediterranean fever may also show deposits of amyloid A protein and have reduced amyloiddegrading activity in serum.8
Purified ao-antitrypsin inhibits degradation of serum amyloid A15 and effectively inhibited the amyloid-A-degrading activity of normal serum. Moreover, the negative correlation between the a1-antitrypsin concentration and amyloid-A-degrading activity during changes in disease activity suggests that the ao-antitrypsin concentration regulates the degrading activity. The differences 100. in amyloid-A-degrading activity between patients with rheumatoid arthritis complicated by amyloidosis and those with rheumatoid arthritis alone cannot, however, be explained solely on the basis of the concentration of immunoreactive ot1-antitrypsin.
We thank Dr Borje Skogen for the purified amyloid A protein. Calf blood flow at rest and during postocclusive reactive hyperaemia was measured using an electrocardiogramtriggered plethysmograph in 14 patients with polycythaemia (nine with primary disease and five with polycythaemia secondary to cyanotic heart disease) before and after a course of venesection. The mean packed cell volume was reduced from 0-57 to 0-47, and whole-blood viscosity fell by 50% at low shear rates.
Venesection did not affect rest flow, but peak flow was increased by 18%. The increase in peak flow failed to compensate for the reduced haemoglobin content of the blood, calculated haemoglobin delivery being reduced by 23% at rest and 10% during reactive hyperaemia. Introduction Polycythaemia, whether primary or secondary, is associated with both a rise in whole-blood viscosity and an increase in thrombotic events.'-3 Cerebral blood flow is reduced in patients with a raised packed cell volume and may return to normal after venesection.46 Peripheral blood flow may be reduced in polycythaemia,7 and this has been presumed to be directly related to hyperviscosity.7 8 Severe intermittent claudication is associated with increased whole-blood viscosity,9 and venesection may improve calf blood flow and haemoglobin delivery.'0 Reduction of packed cell volume and hence viscosity by infusion of low-molecular-weight dextran also increased peripheral blood flow temporarily in patients with claudication.11
In this study we examined the influence of venesection on calf blood flow in patients with primary and secondary polycythaemia using a sensitive plethysmograph.
